👵👴 In a pragmatic 🇩🇰 RCT of 131k adults ≥60y, RSVpreF vaccine 💉 reduced: ➡️ RSV hosp by 83% ➡️ LRTD hosp by 92% ➡️ All-cause RTD hosp by 15% Safety ✅ Presented today at #ESCCongress 🫀🫁 Out now in @NEJM https://t.co/bQfLBQy9P5 @TorBiering @CTCPR_

DANFLU-2 presented by @TorBiering at #ESCCongress today! Monumental 3-year effort by everyone involved! Out now in @NEJM: https://t.co/m2Hjz4ua2d No sig ⬇️ in hosp for composite of flu or pneumonia, but lower incidence of hosp for cardio-resp disease and flu alone ♥️🫁

In DANFLU-2, high-dose vs standard-dose flu vaccine was associated with 20% lower HF hospitalizations in >10k with HF and >322k without HF @KristofferSkaarup @TorBiering @niklasdj1 @CTCPR_ @matslassen @AM_reimer @fdavidovski_MD @dons_maria https://t.co/8f65FZYT3U

The countdown is on! DANFLU-2 will be presented at #ESCCongress on Saturday! 332,438 adults ≥65 years 👵👴 High-dose vs standard-dose influenza vaccine 💉 Severe outcomes: hospitalizations and deaths 🏥☠️ Design paper: https://t.co/BcqEe1xT8I Look out for simpubs! 👀

🚨 Coming up Saturday at #ESCCongress 🚨 Main results from the DAN-RSV trial 👵👴 (n=131,379; age ≥60) 💉 RSVpreF vaccine vs no vaccine 🏥 Outcomes: RSV-related and all-cause hospitalizations Big news for RSV prevention - 👀 out for simpubs! design 📄: https://t.co/W8JZZdtTEa

In Denmark, CVD affects 11% of the population—but with universal healthcare, registry-based research, and bold public health moves, outcomes are improving. Equity is the next frontier. ❤️ @AM_reimer @Espersen_C @TorBiering https://t.co/GirP5MOUrb

Findings by @matslassen from @CTCPR_ High-dose flu vaccine (QIV-HD) reduced all-cause hospitalizations in adults 65-79, with or without diabetes. In those with diabetes, it also lowered the risk of death + hospitalization for pneumonia/influenza. https://t.co/mvjvgBrDP5

@CTCPR_ is hiring! We’re looking for a passionate project nurse to join our research team. https://t.co/g7O7TywN3n

Elevated plasma apolipoprotein E (apoE) levels in people living with HIV: strong links with biomarkers and HIV-specific risk factors. Study by @AM_reimer from @CTCPR_ highlights the need for further research. #HIV https://t.co/8E2Ad6u8oh

PWH had higher plasma apoE than controls even after adjusting for triglycerides. Further studies are needed to elucidate the clinical impact of high plasma apoE in PWH 🔗 https://t.co/s1x3w0wogH @BNordestgaard @society_eas @ELS_Cardiology

People with HIV have higher plasma levels of apolipoprotein E than controls from the general population and this association is independent of both apolipotein B and triglyceride levels. First PhD-article published in @ATHjournal https://t.co/o75Hvx4FC0

In people with #HIV, 📉low NT-proBNP is associated with an adverse adipose tissue profile—high BMI, central obesity, VAT accumulation and low adiponectin. Check out the newly published article by my mentee, Mads-Holger Bang Jacobsen: https://t.co/vpQiNVlkvs @RigsHeart @CopCard

I will present my abstract “Proteomic Associations of Cardiac Function Trajectories Through Mid- to Late Life” on Sat Nov 11 at 3:00-4:15 pm and hope to see you there! Details available here: https://t.co/ptetg56mRT #AHA23

I am honored to be recognized along with my coauthors at #AHA23 for the highest ranked abstract from Denmark. A special thanks to my mentors, Prof. @TorBiering and Prof. Amil Shah, for their invaluable help along the way!

Results from proteomic analyses looking at biologic differences according to predicted trajectory membership will be presented later this year at #AHA23

Happy to present results from this study early this morning. The poster and presentation is available on the ESC online platform:

Bayesian modelling can identify multidimensionel trajectories of cardiac function that associate differentially with risk of #HFpEF and #HFrEF. This approach has the potential to improve HF risk prediction in the future #ESCCongress2023 #ESCCongress @CIRL_DK @BrighamResearch

“When we account for LVEF, things get interesting!” Amazing presentation by @fdavidovski_MD about the prognostic value of AS in HFrEF. #ESCCongress @CIRL_DK @CopCard @TorBiering

Grateful and proud to be part og Prof. @TorBiering’s incredible team @CIRL_DK. It has been an honor to participate in the groundbreaking and innovative DANFLU trial 💫

Our guiding light @TorBiering with a tour de force on how we can use administrative health registries to conduct streamlined pragmatic trials, greatly exemplified by our #DANFLU and #NUDGE #NUDGEFLU programs with much more to come!